Connect with us

International

Big Pharma vs. Little Cuba: Why Cubans trust vaccines and how they’re helping vaccinate the world

Cuba is acting on the scientific fact that humanity will be safest when all who can be vaccinated are vaccinated. It is following the science and earning…

Published

on

A ground crew member directs the loading of a shipment of Cuba's homegrown COVID-19 vaccines donated to Syria, on the tarmac of the Jose Marti International Airport, in Havana, on Jan. 7, 2022. (AP Photo / Ramon Espinosa)

Vaccines could be saving the world from COVID-19, but they aren’t. Almost everywhere, vaccine access or vaccine hesitancy are our Achilles heels.

Vaccine access correlates to GDP, and higher income countries can strike deals with pharmaceutical companies. Vaccination programs also deploy less of these countries’ health-care budgets — 0.8 per cent versus 56.6 per cent for lower-income countries.


Read more: Cuba's push for coronavirus vaccine sovereignty


By developing and administering its own vaccines, Cuba has ensured affordable coverage (0.84 per cent of health-care costs), despite the United States embargo blocking medical supplies, including during the pandemic.

That same blockade is impeding vaccine export from Cuba and has risked thwarting vaccine import to the island. Despite these challenges, Cuba is now one of the most vaccinated countries in the world.

Cuba’s public health

Vaccine hesitancy is rare in Cuba. Its COVID-19 policies and practices are fundamentally science-based. The Cuban government is garnering public support by protecting its citizens from grave illness and death; one of governments’ primary mandates.

This small nation blocked an Omicron spike through its vaccinations and social hygiene measures.

Not-for-profit and universal, Cuba’s public health incorporates standardized, robust immunization schedules that have been the norm for decades. Many medicines and vaccines in the country are created by publicly funded national labs.

Factual, positive analysis on Cuba typically draws fire internationally, with critics objecting that its government controls information.

A girl sits on a hospital bed, wearing a face mask with her legs crossed. A clown wearing yellow entertains her.
A girl is entertained by clowns as she waits after being injected with a dose of the Soberana-02 vaccine for COVID-19 in Havana, Cuba, in August 2021. (AP Photo/Ramon Espinosa)

Why Cubans trust vaccines

In December 2021 and January 2022, I asked open-ended questions directly to 40 Cuban residents — acquaintances, colleagues and friends from my more than 20 years studying Cuban culture and, since 2020, Cuba’s COVID-19 response.

In January and February, I collected 40 anonymous responses via a VoIP survey with the assistance of my colleague Alejandro Mestre. While not statistically representative, this study is indicative. Every respondent — even government naysayers — wanted to be vaccinated.

As she rubbed the veins of her inner forearm, an office worker joked: “Yes, everyone has confidence in the vaccines. You know, sometimes I think, because the Cuban doctors know us, the vaccines have a component of us in them.”


Read more: The scene from Cuba: How it's getting so much right on COVID-19


This widespread, popular confidence is based on lived experience.

Since the 1960s, Cubans have followed a robust vaccine scheme from childhood onward, with the subsequent experience of protection from contagious disease. In one respondent’s words, “I am not sure of the effectiveness of this vaccine, nevertheless, I know that in my country we have been making globally recognized vaccines for many years.”

Residents often compare Cuba with other countries. Many have travelled abroad, including those in the Henry Reeve Brigade — a group of Cuban medical professionals, deployed worldwide during major health crises with the mission of international medical solidarity — and confronted deadly outbreaks like COVID-19. Many also have loved ones abroad and see the difference between the low contagion rates in their country versus the higher rates in countries without widespread vaccination.

Inhabitants of this tropical, middle-income island have personal experiences with infectious diseases, including meningitis (Cuba developed a vaccine) and dengue (Cuba developed public health measures and a medication, interferon alpha-2b).

Why Cubans trust vaccines: Clear messaging

Messaging about the benefits of vaccination, and other public health practices, for individual and societal good is clear and constant in Cuba.

It includes news briefings from the national director of epidemiology, Dr. Francisco Duran, infomercials, popular songs and billboards and human-focused documentaries about doctors in COVID-19 wards like Volverán los abrazos (hugs will return) and on the scientists developing vaccines, like Soberania (which means sovereignty). Further, the respondents of my inquiry believe that Cubans don’t pay much attention to fake news about vaccines that arrives from abroad via social media.

Although not mandated, vaccination is the norm. Primary care providers must obtain an informed consent waiver from patients who decline inoculation and there is peer pressure.

One interviewee wrote, “In the situation in which this pandemic has placed the world, there is no space not to get vaccinated. It is very egotistical.” Another added, “The liberty of every person must not curtail the liberty of others.”

Most Cubans trust in the expertise of their densely woven and interconnected web of health services. “In Cuba, one might die from lack of specialized machines or medicine, but not from lack of specialized, human care,” said one respondent.

Even Cubans who are skeptical of their government in other areas stated that the only reason for Cuban medical experts to do their work is to save lives. In contrast, many talked about how financial interests play into health care in other countries, making it potentially less trustworthy.

Two movie posters, the one on the right depicts a small island with dancers in the background, the one on the left depicts two masked people breathing the same air
Two recent Cuban documentaries, ‘Volverán los abrazos’ which embeds viewers in the daily lives of COVID ward doctors early on in the pandemic. ‘Soberanía’ follows the challenges and triumphs of scientists developing vaccines. (ICAIC)

Cuba’s vaccine rollout

In Cuba, the immunization campaign continues. Cuba began vaccinating children two years and older in September 2021, well before most other — and much richer — countries. It’s now running Phase 2 clinical trials with children under age two.

Cuba is not putting its children at risk; it’s using time-tested research — vaccine platforms used previously for other vaccines — to ensure everyone gets vaccinated as quickly and as safely as possible.

And, while subunit vaccines are considered slow to create and the U.S. embargo slowed development and rollout, Cuba beat other protein subunit vaccines to the finish line.

Developers of U.S.-based Corbevax scrambled for investors to enable research and development, while Cuban national labs simply pivoted to meet the need.


Read more: CORBEVAX, a new patent-free COVID-19 vaccine, could be a pandemic game changer globally


Subunit vaccines have incredible promise as workhorses. Although harder to tweak than mRNA, they are cheaper, less finicky and have much longer track records, the latter of which is particularly relevant for vaccinating children.

While Cubans trust their health experts, the international pharmaceutical industry’s track record — recently with their role in the opioid crisis — is fuelling popular skepticism towards vaccines, also among minority groups.

The idea that market-driven innovation facilitated mRNA technology is misleading. Hungarian-American biochemist Katalin Kariko, whose research enabled mRNA vaccines and who is a contender for a Nobel Prize, struggled for funding, as have other innovators.

Cuba continues working to stop the pandemic, exporting vaccines and transferring production technology to countries including Argentina, Bolivia, Iran, Mexico, Nicaragua, Syria, Venezuela and Vietnam. It’s acting on the scientific fact that humanity will be safest when all who can be vaccinated are vaccinated. Cuba is following the science and earning its trusted reputation.

Jennifer Ruth Hosek does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Read More

Continue Reading

International

Analyst reviews Apple stock price target amid challenges

Here’s what could happen to Apple shares next.

Published

on

They said it was bound to happen.

It was Jan. 11, 2024 when software giant Microsoft  (MSFT)  briefly passed Apple  (AAPL)  as the most valuable company in the world.

Microsoft's stock closed 0.5% higher, giving it a market valuation of $2.859 trillion. 

It rose as much as 2% during the session and the company was briefly worth $2.903 trillion. Apple closed 0.3% lower, giving the company a market capitalization of $2.886 trillion. 

"It was inevitable that Microsoft would overtake Apple since Microsoft is growing faster and has more to benefit from the generative AI revolution," D.A. Davidson analyst Gil Luria said at the time, according to Reuters.

The two tech titans have jostled for top spot over the years and Microsoft was ahead at last check, with a market cap of $3.085 trillion, compared with Apple's value of $2.684 trillion.

Analysts noted that Apple had been dealing with weakening demand, including for the iPhone, the company’s main source of revenue. 

Demand in China, a major market, has slumped as the country's economy makes a slow recovery from the pandemic and competition from Huawei.

Sales in China of Apple's iPhone fell by 24% in the first six weeks of 2024 compared with a year earlier, according to research firm Counterpoint, as the company contended with stiff competition from a resurgent Huawei "while getting squeezed in the middle on aggressive pricing from the likes of OPPO, vivo and Xiaomi," said senior Analyst Mengmeng Zhang.

“Although the iPhone 15 is a great device, it has no significant upgrades from the previous version, so consumers feel fine holding on to the older-generation iPhones for now," he said.

A man scrolling through Netflix on an Apple iPad Pro. Photo by Phil Barker/Future Publishing via Getty Images.

Future Publishing/Getty Images

Big plans for China

Counterpoint said that the first six weeks of 2023 saw abnormally high numbers with significant unit sales being deferred from December 2022 due to production issues.

Apple is planning to open its eighth store in Shanghai – and its 47th across China – on March 21.

Related: Tech News Now: OpenAI says Musk contract 'never existed', Xiaomi's EV, and more

The company also plans to expand its research centre in Shanghai to support all of its product lines and open a new lab in southern tech hub Shenzhen later this year, according to the South China Morning Post.

Meanwhile, over in Europe, Apple announced changes to comply with the European Union's Digital Markets Act (DMA), which went into effect last week, Reuters reported on March 12.

Beginning this spring, software developers operating in Europe will be able to distribute apps to EU customers directly from their own websites instead of through the App Store.

"To reflect the DMA’s changes, users in the EU can install apps from alternative app marketplaces in iOS 17.4 and later," Apple said on its website, referring to the software platform that runs iPhones and iPads. 

"Users will be able to download an alternative marketplace app from the marketplace developer’s website," the company said.

Apple has also said it will appeal a $2 billion EU antitrust fine for thwarting competition from Spotify  (SPOT)  and other music streaming rivals via restrictions on the App Store.

The company's shares have suffered amid all this upheaval, but some analysts still see good things in Apple's future.

Bank of America Securities confirmed its positive stance on Apple, maintaining a buy rating with a steady price target of $225, according to Investing.com

The firm's analysis highlighted Apple's pricing strategy evolution since the introduction of the first iPhone in 2007, with initial prices set at $499 for the 4GB model and $599 for the 8GB model.

BofA said that Apple has consistently launched new iPhone models, including the Pro/Pro Max versions, to target the premium market. 

Analyst says Apple selloff 'overdone'

Concurrently, prices for previous models are typically reduced by about $100 with each new release. 

This strategy, coupled with installment plans from Apple and carriers, has contributed to the iPhone's installed base reaching a record 1.2 billion in 2023, the firm said.

More Tech Stocks:

Apple has effectively shifted its sales mix toward higher-value units despite experiencing slower unit sales, BofA said.

This trend is expected to persist and could help mitigate potential unit sales weaknesses, particularly in China. 

BofA also noted Apple's dominance in the high-end market, maintaining a market share of over 90% in the $1,000 and above price band for the past three years.

The firm also cited the anticipation of a multi-year iPhone cycle propelled by next-generation AI technology, robust services growth, and the potential for margin expansion.

On Monday, Evercore ISI analysts said they believed that the sell-off in the iPhone maker’s shares may be “overdone.”

The firm said that investors' growing preference for AI-focused stocks like Nvidia  (NVDA)  has led to a reallocation of funds away from Apple. 

In addition, Evercore said concerns over weakening demand in China, where Apple may be losing market share in the smartphone segment, have affected investor sentiment.

And then ongoing regulatory issues continue to have an impact on investor confidence in the world's second-biggest company.

“We think the sell-off is rather overdone, while we suspect there is strong valuation support at current levels to down 10%, there are three distinct drivers that could unlock upside on the stock from here – a) Cap allocation, b) AI inferencing, and c) Risk-off/defensive shift," the firm said in a research note.

Related: Veteran fund manager picks favorite stocks for 2024

Read More

Continue Reading

International

Major typhoid fever surveillance study in sub-Saharan Africa indicates need for the introduction of typhoid conjugate vaccines in endemic countries

There is a high burden of typhoid fever in sub-Saharan African countries, according to a new study published today in The Lancet Global Health. This high…

Published

on

There is a high burden of typhoid fever in sub-Saharan African countries, according to a new study published today in The Lancet Global Health. This high burden combined with the threat of typhoid strains resistant to antibiotic treatment calls for stronger prevention strategies, including the use and implementation of typhoid conjugate vaccines (TCVs) in endemic settings along with improvements in access to safe water, sanitation, and hygiene.

Credit: IVI

There is a high burden of typhoid fever in sub-Saharan African countries, according to a new study published today in The Lancet Global Health. This high burden combined with the threat of typhoid strains resistant to antibiotic treatment calls for stronger prevention strategies, including the use and implementation of typhoid conjugate vaccines (TCVs) in endemic settings along with improvements in access to safe water, sanitation, and hygiene.

 

The findings from this 4-year study, the Severe Typhoid in Africa (SETA) program, offers new typhoid fever burden estimates from six countries: Burkina Faso, Democratic Republic of the Congo (DRC), Ethiopia, Ghana, Madagascar, and Nigeria, with four countries recording more than 100 cases for every 100,000 person-years of observation, which is considered a high burden. The highest incidence of typhoid was found in DRC with 315 cases per 100,000 people while children between 2-14 years of age were shown to be at highest risk across all 25 study sites.

 

There are an estimated 12.5 to 16.3 million cases of typhoid every year with 140,000 deaths. However, with generic symptoms such as fever, fatigue, and abdominal pain, and the need for blood culture sampling to make a definitive diagnosis, it is difficult for governments to capture the true burden of typhoid in their countries.

 

“Our goal through SETA was to address these gaps in typhoid disease burden data,” said lead author Dr. Florian Marks, Deputy Director General of the International Vaccine Institute (IVI). “Our estimates indicate that introduction of TCV in endemic settings would go to lengths in protecting communities, especially school-aged children, against this potentially deadly—but preventable—disease.”

 

In addition to disease incidence, this study also showed that the emergence of antimicrobial resistance (AMR) in Salmonella Typhi, the bacteria that causes typhoid fever, has led to more reliance beyond the traditional first line of antibiotic treatment. If left untreated, severe cases of the disease can lead to intestinal perforation and even death. This suggests that prevention through vaccination may play a critical role in not only protecting against typhoid fever but reducing the spread of drug-resistant strains of the bacteria.

 

There are two TCVs prequalified by the World Health Organization (WHO) and available through Gavi, the Vaccine Alliance. In February 2024, IVI and SK bioscience announced that a third TCV, SKYTyphoid™, also achieved WHO PQ, paving the way for public procurement and increasing the global supply.

 

Alongside the SETA disease burden study, IVI has been working with colleagues in three African countries to show the real-world impact of TCV vaccination. These studies include a cluster-randomized trial in Agogo, Ghana and two effectiveness studies following mass vaccination in Kisantu, DRC and Imerintsiatosika, Madagascar.

 

Dr. Birkneh Tilahun Tadesse, Associate Director General at IVI and Head of the Real-World Evidence Department, explains, “Through these vaccine effectiveness studies, we aim to show the full public health value of TCV in settings that are directly impacted by a high burden of typhoid fever.” He adds, “Our final objective of course is to eliminate typhoid or to at least reduce the burden to low incidence levels, and that’s what we are attempting in Fiji with an island-wide vaccination campaign.”

 

As more countries in typhoid endemic countries, namely in sub-Saharan Africa and South Asia, consider TCV in national immunization programs, these data will help inform evidence-based policy decisions around typhoid prevention and control.

 

###

 

About the International Vaccine Institute (IVI)
The International Vaccine Institute (IVI) is a non-profit international organization established in 1997 at the initiative of the United Nations Development Programme with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health.

IVI’s current portfolio includes vaccines at all stages of pre-clinical and clinical development for infectious diseases that disproportionately affect low- and middle-income countries, such as cholera, typhoid, chikungunya, shigella, salmonella, schistosomiasis, hepatitis E, HPV, COVID-19, and more. IVI developed the world’s first low-cost oral cholera vaccine, pre-qualified by the World Health Organization (WHO) and developed a new-generation typhoid conjugate vaccine that is recently pre-qualified by WHO.

IVI is headquartered in Seoul, Republic of Korea with a Europe Regional Office in Sweden, a Country Office in Austria, and Collaborating Centers in Ghana, Ethiopia, and Madagascar. 39 countries and the WHO are members of IVI, and the governments of the Republic of Korea, Sweden, India, Finland, and Thailand provide state funding. For more information, please visit https://www.ivi.int.

 

CONTACT

Aerie Em, Global Communications & Advocacy Manager
+82 2 881 1386 | aerie.em@ivi.int


Read More

Continue Reading

International

US Spent More Than Double What It Collected In February, As 2024 Deficit Is Second Highest Ever… And Debt Explodes

US Spent More Than Double What It Collected In February, As 2024 Deficit Is Second Highest Ever… And Debt Explodes

Earlier today, CNBC’s…

Published

on

US Spent More Than Double What It Collected In February, As 2024 Deficit Is Second Highest Ever... And Debt Explodes

Earlier today, CNBC's Brian Sullivan took a horse dose of Red Pills when, about six months after our readers, he learned that the US is issuing $1 trillion in debt every 100 days, which prompted him to rage tweet, (or rageX, not sure what the proper term is here) the following:

We’ve added 60% to national debt since 2018. Germany - a country with major economic woes - added ‘just’ 32%.   

Maybe it will never matter.   Maybe MMT is real.   Maybe we just cancel or inflate it out. Maybe career real estate borrowers or career politicians aren’t the answer.

I have no idea.  Only time will tell.   But it’s going to be fascinating to watch it play out.

He is right: it will be fascinating, and the latest budget deficit data simply confirmed that the day of reckoning will come very soon, certainly sooner than the two years that One River's Eric Peters predicted this weekend for the coming "US debt sustainability crisis."

According to the US Treasury, in February, the US collected $271 billion in various tax receipts, and spent $567 billion, more than double what it collected.

The two charts below show the divergence in US tax receipts which have flatlined (on a trailing 6M basis) since the covid pandemic in 2020 (with occasional stimmy-driven surges)...

... and spending which is about 50% higher compared to where it was in 2020.

The end result is that in February, the budget deficit rose to $296.3 billion, up 12.9% from a year prior, and the second highest February deficit on record.

And the punchline: on a cumulative basis, the budget deficit in fiscal 2024 which began on October 1, 2023 is now $828 billion, the second largest cumulative deficit through February on record, surpassed only by the peak covid year of 2021.

But wait there's more: because in a world where the US is spending more than twice what it is collecting, the endgame is clear: debt collapse, and while it won't be tomorrow, or the week after, it is coming... and it's also why the US is now selling $1 trillion in debt every 100 days just to keep operating (and absorbing all those millions of illegal immigrants who will keep voting democrat to preserve the socialist system of the US, so beloved by the Soros clan).

And it gets even worse, because we are now in the ponzi finance stage of the Minsky cycle, with total interest on the debt annualizing well above $1 trillion, and rising every day

... having already surpassed total US defense spending and soon to surpass total health spending and, finally all social security spending, the largest spending category of all, which means that US debt will now rise exponentially higher until the inevitable moment when the US dollar loses its reserve status and it all comes crashing down.

We conclude with another observation by CNBC's Brian Sullivan, who quotes an email by a DC strategist...

.. which lays out the proposed Biden budget as follows:

The budget deficit will growth another $16 TRILLION over next 10 years. Thats *with* the proposed massive tax hikes.

Without them the deficit will grow $19 trillion.

That's why you will hear the "deficit is being reduced by $3 trillion" over the decade.

No family budget or business could exist with this kind of math.

Of course, in the long run, neither can the US... and since neither party will ever cut the spending which everyone by now is so addicted to, the best anyone can do is start planning for the endgame.

Tyler Durden Tue, 03/12/2024 - 18:40

Read More

Continue Reading

Trending